Albega Medical

Executive Summary

Albega Medical is a German radiopharmaceutical company founded in 2018, developing targeted radioligands for oncology using a theranostic approach. The company's pipeline is in the preclinical stage, focusing on novel compounds for both diagnostic imaging and therapy in cancers with high unmet medical need. Despite limited public information on specific assets or funding history, the company's focus on the growing field of radiopharmaceuticals positions it within a high-interest sector. However, as a private, preclinical-stage company with no disclosed pipeline or clinical data, the investment risk is elevated. The next 12-24 months will be critical for Albega to advance its lead candidate toward IND-enabling studies and secure additional financing to support development.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate IND-enabling studies initiation25% success
• Q4 2026Series A or significant funding round30% success
• Q2 2026Presentation of preclinical data at major oncology conference40% success